Portfolio, which clocked Rs 84 cr in 2015, to sales of ` help strengthen
Zydus' core therapeutic offerings
Ahmedabad-headquartered drug maker Zydus Cadila has acquired six brands
from the Indian unit of US pharmaceutical giant Merck for an undisclosed
amount.
Zydus, in a release late on Wednesday , said it has acquired
Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range from
Merck Sharp and Dohme (MSD). The acquired portfolio . 84 crore in 2015, it
said.clocked in sales of ` The brands fall in men's and women's health, wound
management and cardiovascular therapy segments.
EThad reported in August that MSD was looking to sell a range of
products as part of a rationalisation drive that would see sharper focus on
select core brands.
Its deal with Zydus includes transfer of distribution and
commercialisation rights as well as assignment of trademarks of all the six
brands to Zydus Healthcare in India.
Organon (India), has also transferred the distribution and
commercialisation rights for Deca-Durabolin and Durabolin for Nepal to Zydus.
The acquisition is expected to strengthen Zydus' portfolio in key
therapeutic segments. “We look at this as a great opportunity to strengthen our
core offerings to create value and growth,“ Zydus Healthcare chairman Sharvil
Patel said. The drug maker's share prices closed 0.20% higher at . `350.45 on
the Bombay Stock Exchange.
Recently, Zydus Cadila's research subsidiary Zydus Discovery DMCC was
pulled up by the US Food and Drug Administration.
Source:Economics Time 29th Dec2016
